REG - GlaxoSmithKline PLC - Directorate Change

GSKAnnouncement

04/05/2022 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220504:nRSD2672Ka&default-theme=true

RNS Number : 2672K  GlaxoSmithKline PLC  04 May 2022

Issued: 4 May 2022, London UK - LSE announcement

 

GSK announces Dr Vishal Sikka to join the Board as Non-Executive Director

 

 

GlaxoSmithKline plc (LSE/NYSE: GSK) has today announced that Dr Vishal Sikka,
founder and CEO of Vianai Systems, will join the Board of the Company as a
Non-Executive Director. He will join the Board with effect from the Haleon
demerger.

Vishal has a distinguished background in technology and particularly in the
field of Artificial Intelligence (AI) and Machine Learning, which is central
to GSK's approach to R&D. He is the founder and CEO of Vianai Systems, a
Silicon Valley-based company that provides advanced technological software and
services in AI and Machine Learning to large enterprises around the world.
Prior to founding Vianai Systems, Vishal served as CEO of Infosys and as a
member of the Executive Board of SAP SE. Vishal has a PhD in Artificial
Intelligence from Stanford University and has co-authored several research
abstracts related to AI, technology and database management. He is also
currently a Board member of Oracle Corporation and BMW.

Commenting on the appointment, Sir Jonathan Symonds, Chair of GSK said: "I
am delighted to welcome Vishal to GSK. He is an experienced board director and
an outstanding technologist who has been at the forefront of advanced
technologies such as AI and Machine Learning for decades. Harnessing and
applying these technologies to the discovery and development of new medicines
and vaccines is central to our R&D approach, and Vishal's insight and
expertise will be invaluable as the company accelerates its efforts in this
area."

Vishal's appointment further strengthens the Board's expertise and builds on
other recent Non-Executive Director appointments, including Dr Harry (Hal) C.
Dietz, Professor of Genetic Medicine at The Johns Hopkins University School of
Medicine; Charles (Charlie) Bancroft, former Executive Vice President at
Bristol Myers Squibb (BMS), and Dr Anne Beal, former instructor in paediatrics
at Harvard Medical School and Massachusetts General Hospital, and Chief
Patient Officer at Sanofi.

A further non-executive appointment, with deep biopharma expertise, is
expected in July 2022.

 

 

 

Notes:

 1.  The appointment of Dr Vishal Sikka was made by the Board on the recommendation
     of the Nominations & Corporate Governance Committee. The Committee
     conducted an extensive search and selection process for this appointment,
     using an external search firm, which is a signatory of the Voluntary Code of
     Conduct for Executive Search Firms.  The external search firm provided a
     diverse list of candidates who were approached, evaluated and interviewed,
     against an agreed set of criteria aligned to the Board's target skills matrix.

 2.  The Board has determined that Dr Sikka will be an independent Non-Executive
     Director on appointment in accordance with the UK Corporate Governance Code.

 3.  Dr Sikka will receive the standard basic fee for a Non-Executive Director of
     £95,000 per annum.

     (Dr Sikka will be required to invest in GSK shares in accordance with the
     Company's shareholder approved Non Executive remuneration policy.)

 4.  Membership of other Committees will be announced in due course.

 5.  Dr Sikka does not have a service contract. He has a letter of appointment
     which may be viewed by contacting the Company Secretary at the Company's
     registered office.

 6.  There are no further disclosures to be made in respect of Dr Sikka's
     appointment under Listing Rule 9.6.13R.

 

 

About GSK

GSK is a science-led global healthcare company. For further information please
visit www.gsk.com/about-us (https://www.gsk.com/en-gb/about-us/) .

 

 

 GSK enquiries:
 Media enquiries:             Tim Foley         +44 (0) 20 8047 5502  (London)
                              Kathleen Quinn    +1 202 603 5003       (Washington DC)

 Analyst/Investor enquiries:  Nick Stone        +44 (0) 7717 618834   (London)
                              Sonya Ghobrial    +44 (0) 7392 784784   (Consumer)
                              James Dodwell     +44 (0) 20 8047 2406  (London)
                              Mick Readey       +44 (0) 7990 339653   (London)
                              Josh Williams     +44 (0) 7385 415719   (London)
                              Jeff McLaughlin   +1 215 751 7002       (Philadelphia)
                              Frannie DeFranco  +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the Company's Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022
and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAZZGGKRDNGZZG